Investor Presentaiton
FY2023 News Flow
Planned major publications
WCLC (Sep 9-12, 2023)
ENHERTU®
DESTINY-Lung02: HER2 mutant NSCLC, 2L+, Ph2
•
Primary analysis data
Dato-DXd
TROPION-Lung04: NSCLC w/o AGA, 1L+, Ph1
.
Interim data
HER3-DXd
HERTHENA-Lung01: EGFR mutant NSCLC, 3L, Ph2
•.
Primary analysis data
DS-7300 (1-DXd)
Ph1/2
•
SCLC sub-analysis data
Regulatory decisions
DESTINY-Lung01, 02: HER2 mutant NSCLC, 2L+, Ph2
ENHERTU®
•
JP: FY2023 Q2
•
EU: FY2023 H2
VANFLYTAⓇ
QUANTUM-First: AML, 1L, Ph3
•
EU: FY2023 H2
Key data readouts
ENHERTU®
Daiichi-Sankyo
As of Jul 2023
DESTINY-Breast06*: HR+ and HER2 low BC, chemo naïve, Ph3
•
FY2023 H2
TROPION-Breast01*: HR+ and HER2 low or negative BC, 2/3L,
Dato-DXd
Ph3
FY2023 H2
DS-5670
COVID-19 mRNA vaccine, original strain, booster
vaccination, healthy adults, Ph1/2/3
⚫ JP: FY2023 Q2
Bold: update from FY2022 Q4
AGA: actionable genomic alterations, AML: acute myeloid leukemia, BC: breast cancer, HR: hormone receptor,
NSCLC: non-small cell lung cancer, SCLC: small cell lung cancer,
WCLC: World Conference on Lung Cancer
Timeline indicated is based on the current forecast and subject to change.
*Event-driven study
30
50View entire presentation